Investigation of the frequency of hyperuricemia and associated risk factors in patients with psoriatic arthritis
DOI:
https://doi.org/10.18203/2320-6012.ijrms20251280Keywords:
Psoriatic arthritis, Hyperuricemia, Metabolic syndromeAbstract
Background: This study aimed to determine the frequency of and clinical significance of hyperuricemia in psoriatic arthritis (PsA) patients.
Methods: The study included 63 PsA patients. Characteristics of the patients, psoriasis (Pso) and PsA duration, and co-morbidities such as hypertension, diabetes mellitus, dyslipidemia, hypothyroidism and coronary artery disease were collected. Moreover, serum uric acid (SUA) and C-reactive protein (CRP) levels at the time of diagnosis, psoriasis area and severity index (PASI) score, body surface area (BSA), Disease Activity index for Psoriatic Arthritis (DAPSA), and Bath Ankylosing Spondylitis Radiological Index (BASRI-total) score were also recorded.
Results: The mean age of the patients was 46.2±10.6 years. 28 (44.4%) had hyperuricemia, of which 23 (36.5%) were female and 5 (7.9%) were male. The mean SUA level was significantly higher in male patients (p=0.002), whereas hypertension was more prominent in female patients (p=0.010). There was no significant relationship between hyperuricemia and BSA, PASI and DAPSA score. PsA patients with hyperuricemia had a high significant difference in BMI (p=0.045) and hypertension (p=0.044). BASRI score was significantly related to age, body mass index, DAPSA score, plantar fascia, greater trochanter, and the Achilles enthesitis (p<0.001, p=0.005, p=0.001, p=0.015, p=0.016 and p=0.031, respectively). On regression analysis, only BMI was associated with SUA level (p=0.043).
Conclusions: The majority of PsA patients had asymptomatic hyperuricemia. Moreover, hyperuricemia was associated with BMI and hypertension. The higher rate of hyperuricemia in women than men seems to be due to their higher BMI values.
Metrics
References
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-70. DOI: https://doi.org/10.1056/NEJMra1505557
Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-65.e19. DOI: https://doi.org/10.1016/j.jaad.2018.06.027
Mistegård J, Gudbjornsson B, Lindqvist U, Laasonen L, Ejstrup L, Ståhle M, et al. Comorbidities in a cohort of 66 patients with psoriatic arthritis mutilans-results from the Nordic PAM Study. Front Med (Lausanne). 2021:8:629741. DOI: https://doi.org/10.3389/fmed.2021.629741
Eder L, Gladman DD. Psoriatic arthritis: phenotypic variance and nosology. Curr Rheumatol Rep. 2013;15(3):316. DOI: https://doi.org/10.1007/s11926-013-0316-4
5. Ohara Y, Kishimoto M, Takizawa N, Yoshida K, Okada M, Eto H, et al. Prevalence and clinical characteristics of psoriatic arthritis in Japan. J Rheumatol. 2015;42(8):1439-42. DOI: https://doi.org/10.3899/jrheum.141598
Kerschbaumer A, Fenzl KH, Erlacher L, Aletaha D. An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets. Wien Klin Wochenschr. 2016;128(21-22):791-5. DOI: https://doi.org/10.1007/s00508-016-1111-9
Song Z, Deng X, Xie W, Li B, Zhang Z. Clinical Characteristics of Psoriatic Arthritis in Chinese Patients: A Cross-Sectional Study. Rheumatol Ther. 2021;8(4):1845-57. DOI: https://doi.org/10.1007/s40744-021-00384-y
ElSherbiny DA, Elsayed AMA, El-Azizi NO, Ghalwash RA. Clinical and laboratory characteristics of psoriatic arthritis in a cohort of Egyptian patients. Egypt Rheumatol. 2021;43(3):229-34. DOI: https://doi.org/10.1016/j.ejr.2021.03.003
Sulaiman W, Tan LK, Mat H, Tohar N, Fati AM, Kosenin NMA, et al. Clinical characteristics and comorbidities in psoriatic arthritis: Experience from a single rheumatology centre in Malaysia. Egypt Rheumatol. 2023;45(4):309-13. DOI: https://doi.org/10.1016/j.ejr.2023.08.002
Tripolino C, Ciaffi J, Ruscitti P, Giacomelli R, Meliconi R, Ursini F. Hyperuricemia in Psoriatic Arthritis: Epidemiology, Pathophysiology, and Clinical Implications. Front Med (Lausanne). 2021;8:737573. DOI: https://doi.org/10.3389/fmed.2021.737573
Lai TL, Yim CW, Wong PY, Leung MC, Ng WL. Hyperuricemia in Asian psoriatic arthritis patients. Int J Rheum Dis. 2018;21(4):843-9. DOI: https://doi.org/10.1111/1756-185X.13265
Raychaudhuri SP. Comorbidities of psoriatic arthritis -metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39(2):437-40. DOI: https://doi.org/10.3899/jrheum.111244
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945-60. DOI: https://doi.org/10.1001/jama.2020.4006
Woo YR, Park CJ, Kang H, Kim JE. The risk of systemic diseases in those with psoriasis and psoriatic arthritis: from mechanisms to clinic. Int J Mol Sci. 2020;21(19):7041. DOI: https://doi.org/10.3390/ijms21197041
Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int. 2021;41(2):275-84. DOI: https://doi.org/10.1007/s00296-020-04775-2
Smiyan SI, Bilukha AV, Koshak BO. Modern determinants of cardiovascular risk factors in patients with psoriatic arthritis: Relation to disease activity and severity. Egypt Rheumatol. 2024;46(1):1-5. DOI: https://doi.org/10.1016/j.ejr.2023.11.001
Ibrahim SE, Helmi A, Yousef TM, Hassan MS, Farouk N. Association of asymptomatic hyperuricemia and endothelial dysfunction in psoriatic arthritis. Egypt Rheumatol. 2012;34(2):83-9. DOI: https://doi.org/10.1016/j.ejr.2012.03.002
Felten R, Duret PM, Gottenberg JE, Spielmann L, Messer L. At the crossroads of gout and psoriatic arthritis: "psout". Clin Rheumatol. 2020;39(5):1405-13. DOI: https://doi.org/10.1007/s10067-020-04981-0
Ataseven A, Kesli R, Kurtipek GS, Ozturk P. Assessment of lipocalin 2, clusterin, soluble tumor necrosis factor receptor-1, interleukin-6, homocysteine, and uric acid levels in patients with psoriasis. Dis Markers. 2014;2014:541709. DOI: https://doi.org/10.1155/2014/541709
Solak B, Dikicier BS, Erdem T. Impact of elevated serum uric acid levels on systemic inflammation in patients with psoriasis. Angiol. 2017;68(3):266-70. DOI: https://doi.org/10.1177/0003319716657980
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-73. DOI: https://doi.org/10.1002/art.21972
Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol. 1991;124:565-70. DOI: https://doi.org/10.1111/j.1365-2133.1991.tb04952.x
23. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238-44. DOI: https://doi.org/10.1159/000250839
Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441-7. DOI: https://doi.org/10.1136/ard.2009.122259
MacKay K, Mack C, Brophy S, Calin A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum. 1998;41(12):2263-70. DOI: https://doi.org/10.1002/1529-0131(199812)41:12<2263::AID-ART23>3.3.CO;2-9
Tsuruta N, Imafuku S, Narisawa Y. Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. J Dermatol. 2017;44(12):1349-52. DOI: https://doi.org/10.1111/1346-8138.13968
Lambert JR, Wright V. Serum uric acid levels in psoriatic arthritis. Ann Rheum Dis. 1977;36(3):264-7. DOI: https://doi.org/10.1136/ard.36.3.264
Bruce IN, Schentag CT, Gladman DD. Hyperuricemia in psoriatic arthritis: prevalence and associated features. J Clin Rheumatol. 2000;6(1):6-9. DOI: https://doi.org/10.1097/00124743-200002000-00001
Gudu T, Peltea A, Balanescu A, Bojinca V, Opris-Belinski D, Predeteanu D, et al. Hyperuricemia in psoriatic arthritis: prevalence and associated factors. Ro J Rheumatol. 2017;26(4):160-3. DOI: https://doi.org/10.37897/RJR.2017.4.4
AlJohani R, Polachek A, Ye JY, Chandran V, Gladman DD. Characteristic and outcome of psoriatic arthritis patients with hyperuricemia. J Rheumatol. 2018;45(2):213-7. DOI: https://doi.org/10.3899/jrheum.170384
Chu BBR, Pereira da Cunha JPVV, Marcon JMT, Eduarda de Arruda Prado L, Rosa FLS, Leitão JM, et al. Does disease activity influence the levels of uric acid in psoriatic arthritis? Open Rheumatol J. 2021;15(1):57-64. DOI: https://doi.org/10.2174/1874312902115010057
Widawski L, Fabacher T, Spielmann L, Gottenberg JE, Sibilia J, Duret PM, et al. Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat. Clin Rheumatol. 2022;41(5):1421-9. DOI: https://doi.org/10.1007/s10067-022-06061-x
Dehlin M, Fasth AER, Reinhardt M, Jacobsson LTH. Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis-a post-hoc analysis of pooled data from three phase 3 trials with secukinumab. Rheumatol Adv Pract. 2021;5(1):rkab009. DOI: https://doi.org/10.1093/rap/rkab009
Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Gomez-Acebo I, Miranda-Filloy JA, Paz-Carreira J, et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum. 2009;39(3):157-62. DOI: https://doi.org/10.1016/j.semarthrit.2008.06.001
Kaine J, Song X, Kim G, Hur P, Palmer JB. Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. Administrative Claims Data. J Manag Care Spec Pharm. 2019;25(1):122-32. DOI: https://doi.org/10.18553/jmcp.2018.17421
Downloads
Published
How to Cite
Issue
Section
